SPY464.60+5.63 1.23%
DIA351.19+2.17 0.62%
IXIC15,782.83+291.18 1.88%

HC Wainwright & Co. Maintains Neutral on Eloxx Pharmaceuticals, Lowers Price Target to $2

HC Wainwright & Co. analyst Andrew Fein maintains Eloxx Pharmaceuticals (NASDAQ:ELOX) with a Neutral and lowers the price target from $3 to $2.

Benzinga · 11/11/2021 06:40
HC Wainwright & Co. analyst Andrew Fein maintains Eloxx Pharmaceuticals (NASDAQ:ELOX) with a Neutral and lowers the price target from $3 to $2.